"T'EMPUS EU/UK Requisition Form — 2025.06.23.

Phone: +1 800.739.4137 | Fax: +1 800.893.0276 | support@tempus.com

If information is incomplete or missing, testing may be delayed.

A.PATIENT INFORMATION														
Last Name				MI		First Name								
DOB (DD/MM/YYYY)	Medical Record # Biolog		iological Sex			Email						Phone		
Address (Street, Unit)				City				Stat	te	Postal Code		Country		
B.ORDERING PHYSICIAN														
Distributor				Ordering Physician (full legal name)							Phone	e		
Facility Name			Tempus	Tempus Account #			Email (required for report o			delivery) F.		ax		
Facility Address (Street, Unit)			City	City				Post	Postal Code			Country		
Additional person to be copied  Name			Email/Fa	ax		Facility Name			ility Name					
Form completed by														
Name				Email/Fax Facility Name										
C.TESTING OPTIONS														
Common test combinations Test descriptions			s				Spe	ecimen re	quired	Optional add-on tests (s		1		
			sequencing test with normal match; ptome RNA sequencing test.			FFPE Tissue; Normal: Blood			or Saliva Tissue Based Ons:		d Add-	I- Algorithmic Add-Ons:		
Add xF liquid biopsy at time of order, based on the following:  I believe it is medically necessary to order a liquid biopsy test concurrently with a solid tumor tissue test because of one or more the use of testing in this disease state; (b) turnaround time for tissue result may delay a treatment decision for my patient; (c) the tissue) and I may not have a timely result to make a treatment decision for my patient; (d) genomic heterogeneity may cause the representative, and I want to make sure I have a complete mutation profile.  If I have not already ordered an xF test above, I opt to convert my xT solid tumor order to an xF liquid biopsy test if necessary:  By converting immediately OR After an additional tissue request is attempted						tissue is at risk to fail (e.g. small tissue, archived			, archived	PD-L1 IHC <sup>1</sup> :		HRD¹³ Tumor Origin (RNA) DPYD¹ UGT1A1¹  1 See our Testing Resources website for IHC and FISH tests ordered by cancer type, and		
XI (DNA) & XR (RNA): Solid Tumor test.				encing test; xR: whole transcriptome RNA			- FFPE TISSUE			CLDN18 IHC FDA <sup>2</sup> _ c-MET IHC FDA <sup>2</sup>		Algorithmic Add-On logistics.  2 Powered by NeoGenomics.  3 Normal sample is required for ovarian and		
xE (DNA) & xR (RNA): Solid Tumor/Normal xE: over 19,000-gene who xR: whole transcriptome R				e exome DNA sequencing test with norr NA sequencing test.			al match; FFPE Tissue; Normal: Blood or Saliva					breast cand		
Individual test options														
xR (RNA Only): Solid Tumor		FFP	E Tissue											
xT (DNA Only): Solid Tumor 648-gene DNA sequencing				test. FFPE Tissue										
xF (Liquid Biopsy): OR xF+ (Liquid Biopsy): xF: 105-gene or xF+: 523-g			: 523-gene liquid b	ene liquid biopsy test for solid tumors. Blood (Streck)										
xE (DNA Only): Solid Tumor/Normal Over 19,000-gene whole e			vhole exome DNA s	xome DNA sequencing test with normal ma				match. FFPE Tissue; Normal: Blood or Saliva						
D.SPECIMEN RETRIEVAL	. See Tempus' specime	en guidelines for	r collection instr	uctions a	nd further	details.								
FFPE Tissue														
Option 1: Specific specimen requested	Option 1: Option 2:		Option 3:	3:		Pathology Lab (Name, City)		, City)	<i>t</i> )					
	choose specimen	Bi	iopsy to be sche	o be scheduled for:		Case Number			Block #			Date of	Date of Collection	
Blood						Saliva						-		
Sample previously submitted Date of Collection:						Send saliva kit to patient Date of Collection:								
E.CURRENT DIAGNOSIS														
Breast NSCLC Colorectal Ovarian	Pancreatic C Prostate	Other:		Primary ICD-10 (		Codes (C & D codes only)				_		III Other: IV		
Disease Status (select all that apply):  Metastatic Relapse Other:				Has the patient had any type of No				Co			chments Copy of patient's progress notes and/or medical records.			
Refractory Recurrent Yes —Type						Copy of red					ecent patho	logy report		
F.BILLING INFORMATIO														
Primary Insurance Plan Name Policy #										y Holder Name			Policy Holder DOB	
Patient Relationship to Policy Holder  Self Spouse Child Other:						Bill Type:  Insurance Hospital/Institution Self pay/International								
G.PHYSICIAN SIGNATURE AND CONSENT														
I certify that the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s). My signature certifies medical necessity of the test(s) (including that the test results will inform the treatment plan) and further certifies that I am authorized to order the test(s) and that the patient has provided informed consent that meets the requirements of						Ordering Physician Signature								
applicable law for Tempus or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) necessary for reimbursement or the processing of insurance claims (if applicable); and (c) collect, use, and retain samples an information obtained from the patient, all in accordance with the Tempus Consent to Genomic Testing form signed by the pati						Printed Name (full legal name) Today's Date (DD/MM/YY						Date (DD/MM/YYYY)		